New England Journal of Medicine· 2005Q1

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Roger Stupp, Warren Mason, Martin J. van den Bent, Michael Weller et al.

21,799citations
Q1SCImago
2005year

Short summary

Adding temozolomide to radiotherapy significantly improved overall survival for glioblastoma patients, extending median survival by 2.5 months (14.6 vs. 12.1 months) and doubling the 2-year survival rate (26.5% vs. 10.4%).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Genetics

GeneticsMedicine